From Backpacks to Pig Kidneys: How Science Is Reimagining Kidney Care

Scientists are developing portable artificial kidneys, genetically modified pig organs, and implantable devices that could transform treatment for the 850 million people worldwide living with kidney disease. These breakthrough technologies aim to replace the current system where patients spend hours three times weekly at dialysis centers or wait years for transplants that may never come.

What Makes These New Artificial Kidneys Different?

Traditional dialysis machines weigh several hundred pounds and stand 5 feet tall, making them impossible to carry around. The University of Washington's Center for Dialysis Innovation (CDI) has created a backpack-sized device called AKTIV (Ambulatory Kidney to Increase Vitality) that could free patients from clinic visits entirely.

"Our breakthrough technology that we think will allow wearability and portability is the new approach to eliminating urea and other toxins from the dialysate," said Dr. Jonathan Himmelfarb, professor of nephrology at the University of Washington School of Medicine. "Instead of having hundreds of liters of dialysate go down the drain, we have created a closed-loop system of a liter of dialysate that continuously recirculates while uremic toxins are removed and transformed into nitrogen and carbon dioxide."

The CDI device has already won three prizes from KidneyX, a public-private partnership seeking to accelerate kidney innovation. The team hopes to begin clinical trials within two years.

How Could Implantable Kidneys Work Inside Your Body?

The Kidney Project at the University of California, San Francisco is developing an even more ambitious solution: a surgically implantable bioartificial kidney that works continuously without external power sources or anti-rejection drugs.

The device combines silicon nanotechnology-based filters with living kidney cells. The silicon membranes feature kidney-like, slit-shaped pores that precisely filter blood while protecting the internal cells from the patient's immune system.

"The pores in our silicon membrane are big enough to allow nutrients, waste, and excess fluids to move between the bloodstream and the bladder through our device, but the pores in the membrane are small [enough] to keep out the immune components," explained Dr. Shuvo Roy, who leads The Kidney Project.

Meanwhile, another company is developing the Holly system, an implantable dialysis device that received FDA Breakthrough Device Designation. This device is designed to work continuously inside the body, mimicking natural kidney function by filtering waste and balancing fluids. Human studies may begin as early as 2027.

Are Pig Kidney Transplants Really Happening?

With over 103,000 people waiting for kidney transplants and only about 1 in 3 receiving one each year, scientists are exploring xenotransplantation—using animal organs in humans.

In 2025, the FDA approved the first clinical trials for genetically modified pig kidneys. These organs are altered to reduce rejection risk and function better in human bodies. A woman became the third person to receive a gene-edited pig kidney in November 2024 and continues to do well.

The National Kidney Foundation is also investing in technologies to make better use of human donor kidneys. Currently, about 1 in 5 donated kidneys go to waste due to transportation delays, storage issues, or quality concerns.

Several companies are working to solve these problems:

• Temperature Control: Diatiro's Kidney Pod maintains optimal cold temperatures during surgery, while Northernmost's NoMo Kidney Pump creates a portable system that fits under airplane seats
• Extended Preservation: 34 Lives and ZeitLife are developing normothermic machine perfusion systems that keep kidneys at body temperature with oxygen and nutrients, potentially rehabilitating 50% of currently discarded organs
• Real-Time Tracking: MediGO uses GPS monitoring to reduce transportation delays and help doctors prepare for surgery

These innovations could dramatically improve outcomes for kidney patients. Continuous filtration more closely mimics natural kidney function, reducing cardiovascular stress and improving blood pressure control compared to intermittent dialysis.

"The bioartificial kidney will dramatically improve patient outcomes by providing continuous kidney-like filtration and reducing the complications associated with traditional dialysis," said Dr. Roy. "Patients will experience greater freedom, increased mobility, fewer hospital visits, and an enhanced quality of life overall."

While most of these technologies are still in development, the progress represents hope for millions of people whose lives are currently dominated by dialysis schedules or transplant waiting lists. With continued funding and successful clinical trials, these innovations could transform kidney care within the next decade.